Critical Comparison: Allena Pharmaceuticals (ALNA) & Champions Oncology (CSBR)

Allena Pharmaceuticals (NASDAQ:ALNA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation & Earnings

This table compares Allena Pharmaceuticals and Champions Oncology’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allena Pharmaceuticals N/A N/A -$21.65 million ($4.80) -1.68
Champions Oncology $20.24 million 7.77 -$1.47 million ($0.14) -100.64

Champions Oncology has higher revenue and earnings than Allena Pharmaceuticals. Champions Oncology is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Allena Pharmaceuticals and Champions Oncology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allena Pharmaceuticals 0 0 7 0 3.00
Champions Oncology 0 0 3 0 3.00

Allena Pharmaceuticals presently has a consensus target price of $31.67, indicating a potential upside of 293.37%. Champions Oncology has a consensus target price of $11.00, indicating a potential downside of 21.93%. Given Allena Pharmaceuticals’ higher possible upside, equities analysts clearly believe Allena Pharmaceuticals is more favorable than Champions Oncology.

Institutional and Insider Ownership

84.9% of Allena Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.7% of Champions Oncology shares are owned by institutional investors. 36.7% of Allena Pharmaceuticals shares are owned by insiders. Comparatively, 44.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Allena Pharmaceuticals and Champions Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allena Pharmaceuticals N/A -73.54% -37.15%
Champions Oncology -1.63% -97.02% -4.66%


Allena Pharmaceuticals beats Champions Oncology on 6 of the 11 factors compared between the two stocks.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Champions Oncology Company Profile

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply